{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-001690","form_type":"8-K","ticker":"SIGY","cik":"0001642159","company_name":"Sigyn Therapeutics, Inc.","filed_at":"2024-01-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.949929+00:00","generated_at":"2026-06-07T02:21:21.125661+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Sigyn Therapeutics shareholder letter details expanded pipeline, S-1 financing, first-in-human study plans","bullets":["Company reveals four therapeutic platforms: Sigyn Therapy, ImmunePrep, ChemoPrep, and ChemoPure, with pending patent for chemotherapy delivery system.","S-1 registration statement filed with SEC to support underwritten financing; proceeds to advance programs and potentially qualify for Nasdaq listing.","First-in-human study of Sigyn Therapy targets ESRD patients with endotoxemia; 12-15 patient IDE drafted for FDA submission.","Clinical sites and principal investigators in place for Sigyn Therapy; treatment to be combined with dialysis.","Pipeline expansion includes devices to enhance performance of immunotherapeutic antibodies and chemotherapy delivery."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-001690","json":"https://secwatch.observer/filing/0001493152-24-001690.json","markdown":"https://secwatch.observer/filing/0001493152-24-001690.md","text":"https://secwatch.observer/filing/0001493152-24-001690.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1642159/000149315224001690/0001493152-24-001690-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1642159/000149315224001690/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T02:21:21.125661+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}